Skip to main content
AAN.com
Views & Reviews
August 13, 2007
Letter to the Editor

Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)

August 14, 2007 issue
69 (7) 693-698

Abstract

Transthyretin familial amyloid polyneuropathies (TTR-FAPs) are autosomal dominant neuropathies of fatal outcome within 10 years after inaugural symptoms. Late diagnosis in patients who present as nonfamilial cases delays adequate management and genetic counseling. Clinical data of the 90 patients who presented as nonfamilial cases of the 300 patients of our cohort of patients with TTR-FAP were reviewed. They were 21 women and 69 men with a mean age at onset of 61 (extremes: 38 to 78 years) and 17 different mutations of the TTR gene including Val30Met (38 cases), Ser77Tyr (16 cases), Ile107Val (15 cases), and Ser77Phe (5 cases). Initial manifestations included mainly limb paresthesias (49 patients) or pain (17 patients). Walking difficulty and weakness (five patients) and cardiac or gastrointestinal manifestations (five patients), were less common at onset. Mean interval to diagnosis was 4 years (range 1 to 10 years); 18 cases were mistaken for chronic inflammatory demyelinating polyneuropathy, which was the most common diagnostic error. At referral a length-dependent sensory loss affected the lower limbs in 2, all four limbs in 20, and four limbs and anterior trunk in 77 patients. All sensations were affected in 60 patients (67%), while small fiber dysfunction predominated in the others. Severe dysautonomia affected 80 patients (90%), with postural hypotension in 52, gastrointestinal dysfunction in 50, impotence in 58 of 69 men, and sphincter disturbance in 31. Twelve patients required a cardiac pacemaker. Nerve biopsy was diagnostic in 54 of 65 patients and salivary gland biopsy in 20 of 30. Decreased nerve conduction velocity, increased CSF protein, negative biopsy findings, and false immunolabeling of amyloid deposits were the main causes of diagnostic errors. We conclude that DNA testing, which is the most reliable test for TTR-FAP, should be performed in patients with a progressive length-dependent small fiber polyneuropathy of unknown origin, especially when associated with autonomic dysfunction.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (e1.doc)

REFERENCES

1.
Andrade C. A peculiar form of peripheral neuropathy: familial atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75:408–427.
2.
Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-Type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet (Neuropsych Genet) 1995;60:512–521.
3.
Holmgren G, Costa PMP, Andersson C, et al. Geographical distribution of TTR met 30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994;31:351–354.
4.
Araki S, Mawatari S, Ohta M, Nakajima A, Kuroiwa Y. Polyneuritic amyloidosis in a Japanese family. Arch Neurol 1968;18:593–602.
5.
Misu K, Hattori N, Nagamatsu M, et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain 1999;122:1951–1962.
6.
Plante-Bordeneuve V, Carayol J, Ferreira A, et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 2003;40:e 120.
7.
Adams D, Reilly M, Harding AE, Said G. Demonstration of genetic mutation in most of the amyloid neuropathies with sporadic occurrence. Rev Neurol (Paris) 1992;148:736–741.
8.
Koike H, Misu K, Ikeda S, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early-versus late onset form. Arch Neurol 2002;59:1771–1776.
9.
Hattori T, Takei Y, Koyama J, Nakazato M, Ikeda S. Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy. Amyloid 2003;10:229–239.
10.
Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002;9:58:1001–1007.
11.
Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000;123:1495–1504.
12.
Sharma P, Perri RE, Sirven JE, et al. Outcome of liver transplantation for familial amyloidotic polyneuropathy. Liver Transpl 2003;9:1273–1280.
13.
Suhr OB, Friman S, Ericzon BG. Early liver transplantation improves familial amyloidotic polyneuropathy patients’ survival. Amyloid 2005;12:233–238.
14.
Said G, Ropert A, Faux N. Length dependent degeneration of fibers in Portuguese amyloid polyneuropathy. A clinicopathological study. Neurology 1984;34:1025–1032.
15.
Said G. Chronic inflammatory demyelinating polyneuropathy. Neuromusc Disord 2006;16:293–303.
16.
Simmons Z, Blaivas M, Aguilera AJ, Feldman EL, Bromberg MB, Towfighi J. Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis. J Neurol Sci 1993;120:60–63.
17.
Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786–1791.
Letters to the Editor
1 November 2007
Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)
Ken Ikeda, Department of Neurology, Toho University Omori Medical Center
Osamu Kano, Hirono Ito, Yuji Kawase, Konosuke Iwamoto, Ryuta Sato, Tokinori Sekine, Ria Nagata, Yoshikazu Nakamura, Takehisa Hirayama, and Yasuo Iwasaki.

We read the article by Planté-Bordeneuve et al. with great interest. [1] We reported a unique patient with sporadic TTR (Val30Met) -FAP [2] and have inquiries regarding the sporadic patients of Planté-Bordeneuve et al. [1]

Our patient, a 72-year-old man, developed dysesthesisa and weakness in the feet at age sixty-seven. Two years later, severe muscle weakness and loss of sensation progressed rapidly in the four extremities. His family history showed no neurological or cardiac disorders.

Neurological examination showed muscle weakness (MRC 0-1) and profound atrophy in the hands and feet. Muscle stretch reflexes were absent in the four extremities. Dysarthria and dysphagia were found and marked atrophy and fasciculation were seen in the tongue. Pharyngeal reflexes were absent. There were no superficial and proprioceptive sensations in the hands and feet. There was no dysautonomia including postural hypotension, gastrointestinal or sphincter dysfunction.

Cerebrospinal fluid tests showed mild increase of protein (58 mg/dL). Sensory nerve conduction velocities were not evoked in the four extremities. Motor nerve conduction velocities were not evoked in the tibial and peroneal nerves. Needle electromyography revealed positive sharp waves and fibrillation potentials in the distal limb and tongue muscles.

Sural nerve biopsy showed severe loss of myelinated fibers without amyloid deposits. The patient died of renal failure. Immunohistochemical study disclosed TTR-amyloid deposits in the median nerve and the hypoglossal nerve root. Gene analysis of FAP indicated Val30Met mutation. Planté-Bordeneuve et al. review mild dysautonomia and prominent large myelinated fiber sensory loss in late-onset patients with Val30Met FAP-TTR. [1] Those clinical hallmarks are similar to our patient. We would like to know the clinico-pathological findings in patients with senile onset (more than 65 years) among their 90 patients with sporadic FAP. What are the different features between patients with early versus senile onset?

It is interesting that six patients had uncommon cranial nerve involvement. The second question is whether those patients have typical histories of FAP-TTR. Specifically, we would like to see bulbar and limb motor deficits in one patient with the Val30Met mutation and bilateral hypoglossal nerve palsy.

Misdiagnosis of nonfamilial TTR-FAP in senile-onset patients who have rapid progression of sensorimotor neuropathy and normal autonomic function is possible. TTR gene analysis in these patients should be considered to avoid diagnostic delay.

References

1. Planté-Bordeneuve V, Ferreira A, Lalu, T, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007;69:693-698.

2. Ikeda K, Kinoshita M, Takamiya K, et al. Bulbar palsy in senile onset familial amyloid polyneuropathy (30Val�¨Met): transthyretin-amyloid deposits in the hypoglossal nerve root. Eur J Neurol 1998;5:211-214.

Disclosure: The authors report no conflicts of interest.

1 November 2007
Reply from the authors
Violaine Planté-Bordeneuve, Department of Neurology - CHU Bicêtre
Gérard Said

We would like to thank Dr. Ikeda et al. for their interest in our article on sporadic familial amyloid polyneuropathy (FAP). [1] It is difficult to accurately compare the nerve pathology of patients with early and late onset FAP because the interval between performance of the biopsy and the onset of clinical manifestations varies.

However, we also observed that large myelinated fibers are more affected in late onset cases, with less involvement of unmyelinated fibers than in early onset FAP. [3] Cranial nerves are more often affected in late onset FAP with occasionally pure motor neuropathies mimicking motor neuron disease, as we also observed recently (unpublished data).

Therefore, if FAP generally presents as a length dependent sensory-motor polyneuropathy with life threatening autonomic dysfunction, many exceptions occur which may delay diagnosis and treatment. In younger patients, the classic pattern is the most common, while in the elderly presentation it is variable and often misleading with asymmetrical onset, ataxia, or predominantly motor deficit with little or no autonomic dysfunction.

In addition, the clinician must consider the many diagnostic pitfalls in late onset FAP, which is why we shared our experiences.

Reference

3. Said G. Familial amyloid polyneuropathy: mechanisms leading to nerve degeneration. Amyloid 2003; 10, Suppl.1, 7.

Disclosure: The authors report no conflicts of interest.

Information & Authors

Information

Published In

Neurology®
Volume 69Number 7August 14, 2007
Pages: 693-698
PubMed: 17698792

Publication History

Published online: August 13, 2007
Published in print: August 14, 2007

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

V. Planté-Bordeneuve, MD, PhD
From the Centre d’Etude des Neuropathies Amyloïdes Familiales, Service de Neurologie, and Laboratoire Ranvier, Inserm U 788, Hôpital de Bicêtre Assistance Publique Hôpitaux de Paris, Université Paris-Sud, France.
A. Ferreira, MD
From the Centre d’Etude des Neuropathies Amyloïdes Familiales, Service de Neurologie, and Laboratoire Ranvier, Inserm U 788, Hôpital de Bicêtre Assistance Publique Hôpitaux de Paris, Université Paris-Sud, France.
T. Lalu, MD
From the Centre d’Etude des Neuropathies Amyloïdes Familiales, Service de Neurologie, and Laboratoire Ranvier, Inserm U 788, Hôpital de Bicêtre Assistance Publique Hôpitaux de Paris, Université Paris-Sud, France.
C. Zaros, PhD
From the Centre d’Etude des Neuropathies Amyloïdes Familiales, Service de Neurologie, and Laboratoire Ranvier, Inserm U 788, Hôpital de Bicêtre Assistance Publique Hôpitaux de Paris, Université Paris-Sud, France.
C. Lacroix, MD
From the Centre d’Etude des Neuropathies Amyloïdes Familiales, Service de Neurologie, and Laboratoire Ranvier, Inserm U 788, Hôpital de Bicêtre Assistance Publique Hôpitaux de Paris, Université Paris-Sud, France.
D. Adams, MD, PhD
From the Centre d’Etude des Neuropathies Amyloïdes Familiales, Service de Neurologie, and Laboratoire Ranvier, Inserm U 788, Hôpital de Bicêtre Assistance Publique Hôpitaux de Paris, Université Paris-Sud, France.
G. Said, MD
From the Centre d’Etude des Neuropathies Amyloïdes Familiales, Service de Neurologie, and Laboratoire Ranvier, Inserm U 788, Hôpital de Bicêtre Assistance Publique Hôpitaux de Paris, Université Paris-Sud, France.

Notes

Address correspondence and reprint requests to Dr. V. Planté, Service de Neurologie, Hôpital de Bicêtre, 94275 Le Kremlin Bicêtre, France [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. The Gly103Arg variant in hereditary transthyretin amyloidosis, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1471131
    Crossref
  2. Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre, European Journal of Preventive Cardiology, 31, 7, (866-876), (2024).https://doi.org/10.1093/eurjpc/zwae011
    Crossref
  3. T2-relaxometry in a large cohort of hereditary transthyretin amyloidosis with polyneuropathy, Amyloid, 31, 4, (309-317), (2024).https://doi.org/10.1080/13506129.2024.2398453
    Crossref
  4. Altered connectivity of central autonomic network: effects of dysautonomia in hereditary transthyretin amyloidosis with polyneuropathy, Amyloid, 31, 4, (257-265), (2024).https://doi.org/10.1080/13506129.2024.2383450
    Crossref
  5. Diagnostic delay in patients with sporadic hereditary transthyretin-mediated amyloidosis, Neurological Sciences, (2024).https://doi.org/10.1007/s10072-024-07793-1
    Crossref
  6. Chronic Inflammatory Demyelinating Polyneuropathy, Neuroimmune Diseases, (1025-1052), (2024).https://doi.org/10.1007/978-3-031-60006-7_25
    Crossref
  7. Chronic Inflammatory Demyelinating Polyneuropathy, Neuroimmune Diseases, (1-28), (2024).https://doi.org/10.1007/978-3-031-24297-7_25-1
    Crossref
  8. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States : Recommendations from a panel of experts , Muscle & Nerve, 69, 3, (273-287), (2024).https://doi.org/10.1002/mus.28026
    Crossref
  9. Utility of Genetic Testing in Patients with Transthyretin Amyloid Cardiomyopathy: A Brief Review, Biomedicines, 12, 1, (25), (2023).https://doi.org/10.3390/biomedicines12010025
    Crossref
  10. Transthyretin Variant Amyloidosis with a TTR A97D (p.A117D) Mutation Manifesting Remarkable Asymmetric Neuropathy, Internal Medicine, 62, 15, (2261-2266), (2023).https://doi.org/10.2169/internalmedicine.0798-22
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share